{"title":"RUNX1突变对异基因造血干细胞移植治疗急性髓系白血病预后的临床影响","authors":"Wei-Jie Ran, Lan-Ping Xu, Xiao-Hui Zhang, Ying-Jun Chang, Xiao-Dong Mo, Yu-Qian Sun, Xiao-Jun Huang, Yu Wang","doi":"10.3390/curroncol32060294","DOIUrl":null,"url":null,"abstract":"<p><p>It is reported that AML with RUNX1 mutations is associated with poorer response to conventional chemotherapy, lower rates of complete remission (CR), leukemia-free survival (LFS), and overall survival (OS). We aimed to evaluate the prognostic impact of RUNX1 mutations following allogeneic hematopoietic stem cell transplantation (allo-HSCT) by comparing clinical outcomes in AML patients with and without RUNX1 mutations. We retrospectively analyzed 91 AML patients (33 RUNX1+ and 58 RUNX1-) who received their first HSCT at Peking University People's Hospital. The median age of the cohort was 38 years (range: 6-64), with 73 patients (80%) receiving Haploidentical HSCT and 18 patients (20%) receiving sibling-matched allo-HSCT. In univariate analyses, no significant differences in survival outcomes were observed. For the RUNX1-mutation group and RUNX1-wild-type group, the 2-year cumulative incidence of relapse (CIR) was (12.6% vs. 7.6%, <i>p</i> = 0.472), the 2-year non-relapse mortality (NRM) rate was (9.6% vs. 7.2%, <i>p</i> = 0.747), the 2-year LFS was (77.8% vs. 85.2%, <i>p</i> = 0.426), and the 2-year OS rate was (85.9% vs. 92.7%, <i>p</i> = 0.397). We did not observe any negative impact of RUNX1 mutations on clinical outcomes, suggesting that allo-HSCT (especially Haplo-HSCT) may mitigate the adverse prognostic influence of RUNX1 mutations in AML.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12192008/pdf/","citationCount":"0","resultStr":"{\"title\":\"Clinical Effects of RUNX1 Mutations on the Outcomes of Patients with Acute Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem-Cell Transplantation.\",\"authors\":\"Wei-Jie Ran, Lan-Ping Xu, Xiao-Hui Zhang, Ying-Jun Chang, Xiao-Dong Mo, Yu-Qian Sun, Xiao-Jun Huang, Yu Wang\",\"doi\":\"10.3390/curroncol32060294\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>It is reported that AML with RUNX1 mutations is associated with poorer response to conventional chemotherapy, lower rates of complete remission (CR), leukemia-free survival (LFS), and overall survival (OS). We aimed to evaluate the prognostic impact of RUNX1 mutations following allogeneic hematopoietic stem cell transplantation (allo-HSCT) by comparing clinical outcomes in AML patients with and without RUNX1 mutations. We retrospectively analyzed 91 AML patients (33 RUNX1+ and 58 RUNX1-) who received their first HSCT at Peking University People's Hospital. The median age of the cohort was 38 years (range: 6-64), with 73 patients (80%) receiving Haploidentical HSCT and 18 patients (20%) receiving sibling-matched allo-HSCT. In univariate analyses, no significant differences in survival outcomes were observed. For the RUNX1-mutation group and RUNX1-wild-type group, the 2-year cumulative incidence of relapse (CIR) was (12.6% vs. 7.6%, <i>p</i> = 0.472), the 2-year non-relapse mortality (NRM) rate was (9.6% vs. 7.2%, <i>p</i> = 0.747), the 2-year LFS was (77.8% vs. 85.2%, <i>p</i> = 0.426), and the 2-year OS rate was (85.9% vs. 92.7%, <i>p</i> = 0.397). We did not observe any negative impact of RUNX1 mutations on clinical outcomes, suggesting that allo-HSCT (especially Haplo-HSCT) may mitigate the adverse prognostic influence of RUNX1 mutations in AML.</p>\",\"PeriodicalId\":11012,\"journal\":{\"name\":\"Current oncology\",\"volume\":\"32 6\",\"pages\":\"\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-05-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12192008/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/curroncol32060294\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/curroncol32060294","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
据报道,RUNX1突变的AML对常规化疗的反应较差,完全缓解(CR)、无白血病生存(LFS)和总生存(OS)率较低。我们旨在通过比较有RUNX1突变和没有RUNX1突变的AML患者的临床结果来评估RUNX1突变对同种异体造血干细胞移植(alloc - hsct)后预后的影响。我们回顾性分析了91例在北京大学人民医院接受首次造血干细胞移植的AML患者(33例RUNX1+和58例RUNX1-)。队列的中位年龄为38岁(范围:6-64岁),其中73例患者(80%)接受单倍同型HSCT, 18例患者(20%)接受兄弟姐妹匹配的同种异体HSCT。在单变量分析中,没有观察到生存结果的显著差异。对于runx1突变组和runx1野生型组,2年累积复发发生率(CIR)为(12.6% vs. 7.6%, p = 0.472), 2年非复发死亡率(NRM)为(9.6% vs. 7.2%, p = 0.747), 2年LFS为(77.8% vs. 85.2%, p = 0.426), 2年OS为(85.9% vs. 92.7%, p = 0.397)。我们没有观察到RUNX1突变对临床结果的任何负面影响,这表明同种异体hsct(尤其是单倍hsct)可能减轻RUNX1突变对AML预后的不良影响。
Clinical Effects of RUNX1 Mutations on the Outcomes of Patients with Acute Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem-Cell Transplantation.
It is reported that AML with RUNX1 mutations is associated with poorer response to conventional chemotherapy, lower rates of complete remission (CR), leukemia-free survival (LFS), and overall survival (OS). We aimed to evaluate the prognostic impact of RUNX1 mutations following allogeneic hematopoietic stem cell transplantation (allo-HSCT) by comparing clinical outcomes in AML patients with and without RUNX1 mutations. We retrospectively analyzed 91 AML patients (33 RUNX1+ and 58 RUNX1-) who received their first HSCT at Peking University People's Hospital. The median age of the cohort was 38 years (range: 6-64), with 73 patients (80%) receiving Haploidentical HSCT and 18 patients (20%) receiving sibling-matched allo-HSCT. In univariate analyses, no significant differences in survival outcomes were observed. For the RUNX1-mutation group and RUNX1-wild-type group, the 2-year cumulative incidence of relapse (CIR) was (12.6% vs. 7.6%, p = 0.472), the 2-year non-relapse mortality (NRM) rate was (9.6% vs. 7.2%, p = 0.747), the 2-year LFS was (77.8% vs. 85.2%, p = 0.426), and the 2-year OS rate was (85.9% vs. 92.7%, p = 0.397). We did not observe any negative impact of RUNX1 mutations on clinical outcomes, suggesting that allo-HSCT (especially Haplo-HSCT) may mitigate the adverse prognostic influence of RUNX1 mutations in AML.
期刊介绍:
Current Oncology is a peer-reviewed, Canadian-based and internationally respected journal. Current Oncology represents a multidisciplinary medium encompassing health care workers in the field of cancer therapy in Canada to report upon and to review progress in the management of this disease.
We encourage submissions from all fields of cancer medicine, including radiation oncology, surgical oncology, medical oncology, pediatric oncology, pathology, and cancer rehabilitation and survivorship. Articles published in the journal typically contain information that is relevant directly to clinical oncology practice, and have clear potential for application to the current or future practice of cancer medicine.